Results 221 to 230 of about 250,267 (258)
Some of the next articles are maybe not open access.
Kinetics of Minimal Residual Disease
1979The development of a rational approach to adjuvant chemotherapy of cancer depends upon at least four factors: 1. Recognition that micrometastases are frequently disseminated and established prior to the time of surgery for a primary cancer; 2.
openaire +2 more sources
Minimal residual disease in acute leukaemia
European Journal of Cancer and Clinical Oncology, 1991THE PERSISTENCE of leukaemic cells throughout remission of the disease is increasingly recognised by modern methods. In particular polymerase’ chain reaction methodology allows to demonstrate the persistence of a few leukaemic cells (0.004-2.6%) in bone marrow of some patients with complete remission (CR) of acute lymphoblastic leukaemia (ALL) [l]. The
H H, Gerhartz, H, Schmetzer
openaire +2 more sources
Minimal residual disease in gastrointestinal cancer
Seminars in Surgical Oncology, 2001AbstractTumor progression after curative resection of gastrointestinal carcinomas is probably caused by pre‐ or intraoperative tumor cell dissemination. Disseminated tumor cells are generally detected by immunohistochemistry‐ or PCR‐based molecular‐biology methods. A consensus on which is the most adequate detection method has not yet been found, which
P, Kienle, M, Koch
openaire +2 more sources
Advances in the detection of minimal residual disease
Current Opinion in Hematology, 1997The study of minimal residual disease (MRD) is an attempt to detect and define the significance of leukemia invisible to normal morphologic examination. In many circumstances the clinical significance of MRD detection is unclear, because the technical ability to detect and quantify it has outpaced studies demonstrating its clinical significance.
J, Radich, B, Thomson
openaire +2 more sources
2009
During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
Minimal residual disease in thyroid carcinoma
Seminars in Surgical Oncology, 2001AbstractThe detection of disseminated tumor cells in differentiated (DTC) and medullary thyroid carcinomas (MTC) is one of the main topics in current thyroid cancer research. Immunocytochemistry and polymerase chain reaction (PCR) provide the tools for the identification of a small number of thyroid cancer cells in peripheral blood and cervical lymph ...
T, Weber, E, Klar
openaire +2 more sources
Managing Minimal Residual Malignant Disease
Oncology, 2009So-called complete remission of acute leukemia and other tumors frequently leaves minimal residual disease cells, sometimes causing an inflammatory response and often relapse. Although the remaining cells often have long generation times or may even be in G0 condition, they may form a new tumor mass.
G, Mathé, P, Reizenstein
openaire +2 more sources
Detection of minimal residual disease in ALL
1993Complete remission (CR) of acute leukemia is defined in clinical practice as the presence in the bone marrow of less than 5% blast cells, a level determined by the limits of reliable detection by morphology. Mathematical models predict that the level of residual disease during clinical remission could vary from 1010 leukemic cells following early ...
M, Deane, A V, Hoffbrand
openaire +2 more sources
Minimal residual disease in multiple myeloma
La Presse MédicaleMinimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapy, and bispecific antibodies, complete eradication of malignant ...
Nour, Moukalled +3 more
openaire +2 more sources
Minimal Residual Disease in Prostate Cancer
2018Detection of minimal residual disease (MRD) in prostate cancer over several decades has greatly informed our understanding of dissemination and recurrence, but has not yet been routinely used in clinical care. Investigators have detected MRD by identification of prostate cancer cells in the bone marrow; termed disseminated tumor cells (DTCs) and blood;
Frank C, Cackowski, Russell S, Taichman
openaire +2 more sources